###begin article-title 0
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 38 43 <span type="species:ncbi:9606">Human</span>
###xml 83 87 <span type="species:ncbi:10090">Mice</span>
Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: MRS MCA RTW. Performed the experiments: MRS MCA. Analyzed the data: MRS MCA LJG. Contributed reagents/materials/analysis tools: LJG DLG LDS RTW. Wrote the paper: MRS RTW.
###end p 1
###begin p 2
###xml 1047 1050 1043 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1055 1058 1051 1054 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1043 1058 1039 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 414 420 <span type="species:ncbi:10090">murine</span>
###xml 449 454 <span type="species:ncbi:9606">human</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
###xml 617 623 <span type="species:ncbi:10090">murine</span>
###xml 669 674 <span type="species:ncbi:9606">human</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
###xml 704 710 <span type="species:ncbi:10090">murine</span>
###xml 855 860 <span type="species:ncbi:9606">human</span>
###xml 905 911 <span type="species:ncbi:10090">murine</span>
###xml 1010 1015 <span type="species:ncbi:9606">human</span>
###xml 1075 1079 <span type="species:ncbi:10090">mice</span>
###xml 1105 1110 <span type="species:ncbi:9606">human</span>
###xml 1155 1160 <span type="species:ncbi:9606">human</span>
###xml 1199 1204 <span type="species:ncbi:9606">Human</span>
###xml 1468 1472 <span type="species:ncbi:10090">mice</span>
###xml 1523 1528 <span type="species:ncbi:9606">human</span>
The production of fully immunologically competent humanized mice engrafted with peripheral lymphocyte populations provides a model for in vivo testing of new vaccines, the durability of immunological memory and cancer therapies. This approach is limited, however, by the failure to efficiently engraft human B lymphocytes in immunodeficient mice. We hypothesized that this deficiency was due to the failure of the murine microenvironment to support human B cell survival. We report that while the human B lymphocyte survival factor, B lymphocyte stimulator (BLyS/BAFF) enhances the survival of human B cells ex vivo, murine BLyS has no such protective effect. Although human B cells bound both human and murine BLyS, nuclear accumulation of NF-kappaB p52, an indication of the induction of a protective anti-apoptotic response, following stimulation with human BLyS was more robust than that induced with murine BLyS suggesting a fundamental disparity in BLyS receptor signaling. Efficient engraftment of both human B and T lymphocytes in NOD rag1-/- Prf1-/- immunodeficient mice treated with recombinant human BLyS is observed after adoptive transfer of human PBL relative to PBS treated controls. Human BLyS treated recipients had on average 40-fold higher levels of serum Ig than controls and mounted a de novo antibody response to the thymus-independent antigens in pneumovax vaccine. The data indicate that production of fully immunologically competent humanized mice from PBL can be markedly facilitated by providing human BLyS.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 287 291 287 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 282 291 282 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prkdc<sup>scid</sup></italic>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 297 312 297 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 333 336 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 318 336 318 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid IL-2R&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 349 352 345 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 362 363 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 345 363 341 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>IL-2R&#947;<sup>&#8722;</sup></italic>
###xml 364 365 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</italic>
###xml 363 365 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/<italic>&#8722;</italic></sup>
###xml 372 373 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 378 381 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 390 393 378 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 374 393 366 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>IL2R&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 516 519 504 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Shultz1">[1]</xref>
###xml 521 524 509 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Manz1">[2]</xref>
###xml 659 662 647 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Macchiarini1">[3]</xref>
###xml 663 667 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Shultz4">[12]</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 470 475 <span type="species:ncbi:9606">human</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
###xml 833 837 <span type="species:ncbi:10090">mice</span>
The development of a small animal model that reproducibly supports human lymphocyte development and/or peripheral lymphocyte survival and function should lead to improved treatment strategies for human tumors, autoimmune diseases and new vaccines. Immunodeficient mice, such as NOD-Prkdcscid, NOD-rag1-/- Prf1-/-, NOD-scid IL-2Rgamma-/-, Balb/c-rag1-/-IL-2Rgamma-/- and H2d-rag1-/-IL2Rgamma-/- have been used as recipients of human peripheral blood lymphocytes (PBL) or human hematopoietic stem cells (HSC) (reviews [1], [2]). Chimeric mice engrafted with human HSC can support B and T cell development and the survival of peripheral T and B cell populations [3]-[12], however lymphoid development following engraftment is slow (3-6 months) and is of varying efficiency even when the same HSC preparation is used to engraft multiple mice.
###end p 4
###begin p 5
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 667 670 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 675 678 675 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 663 678 663 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag2<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 691 694 691 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 704 707 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 687 707 687 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag2<sup>&#8722;/&#8722;</sup>IL-2r&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 953 954 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1001 1005 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Wagar1">[13]</xref>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 102 108 <span type="species:ncbi:10090">murine</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 341 347 <span type="species:ncbi:9606">humans</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
###xml 1035 1041 <span type="species:ncbi:10090">murine</span>
Conceptually, the engraftment of mature human peripheral blood lymphocytes (PBL) into immunodeficient murine recipients overcomes the need for long reconstitution times required when using human CD34+ cord blood derived HSC and should allow for a rapid assessment of immune responsiveness of diverse individuals, for example, young and aged humans. In addition, the potential to establish primary lymphoid tumors, such as leukemias and lymphomas, in a chimeric host would provide opportunities to investigate the efficacy of novel therapeutic strategies tailored to individual patients. T cell engraftment is frequently observed when PBL are transferred into NOD rag2-/- Prf1-/- and NOD rag2-/-IL-2rgamma-/- mice, whereas B cell homeostasis is abnormal. Mature B cells persist early after PBL transfer and can produce recall and polyclonal immunoglobulin (Ig) responses, however, these B cells are lost within 2 weeks and this loss is accelerated if CD4+ T cells are removed from the initial inoculum [13]. These data suggest that the murine environment may not provide the critical growth factors and/or signaling ligands necessary for B cell homeostasis.
###end p 5
###begin p 6
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Kraus1">[14]</xref>
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Rolink1">[17]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 693 697 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Rolink1">[17]</xref>
###xml 699 703 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Claudio1">[19]</xref>
###xml 704 708 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Sasaki2">[21]</xref>
###xml 861 865 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 867 871 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Gordon1">[22]</xref>
###xml 872 876 868 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Hase1">[24]</xref>
###xml 1037 1041 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 1043 1047 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-ShulgaMorskaya1">[25]</xref>
###xml 1215 1219 1211 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Hase1">[24]</xref>
###xml 1221 1225 1217 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Zhang1">[26]</xref>
###xml 1227 1231 1223 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Avery1">[27]</xref>
###xml 1364 1368 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Stohl1">[28]</xref>
###xml 1369 1373 1365 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Stohl2">[30]</xref>
###xml 1450 1454 1446 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Stewart1">[31]</xref>
###xml 1456 1460 1452 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Losi1">[32]</xref>
###xml 1619 1623 1615 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-He1">[33]</xref>
###xml 1624 1628 1620 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Novak1">[35]</xref>
###xml 1052 1058 <span type="species:ncbi:9606">humans</span>
###xml 1194 1199 <span type="species:ncbi:9606">human</span>
###xml 1480 1485 <span type="species:ncbi:9606">human</span>
Mature B cells are actively maintained in vivo by survival signals received through the B cell antigen receptor (BCR) and a receptor for the TNF family ligand B lymphocyte stimulator, BLyS, also known as BAFF, TALL-1, THANK, TNFSF13B and zTNF4 [14]-[17]. BLyS is a type II protein produced in both membrane-bound and soluble forms by stromal cells, macrophages, dendritic cells and neutrophils [18]. BLyS has two proposed mechanisms of action; to facilitate the differentiation of short-lived immature B cells into mature recirculating long-lived B cells, and to actively maintain mature B cells in the periphery by facilitating their survival through non-canonical NF-kappaB mediated signals [17], [19]-[21]. BLyS dependent survival signals are delivered through the BLyS receptor, BR3 (BAFF-R) that is expressed on late immature and mature peripheral B cells [18], [22]-[24]. Two other receptors for BLyS are also found on B cells, TACI and BCMA, and their expression is associated with different maturation and differentiation states [18], [25]. In humans, BLyS has been shown to be critical for B cell survival, the generation of lymphoid follicles and survival of plasmablasts formed from human memory B cells [24], [26], [27]. Overexpression of BLyS has been correlated with autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis [28]-[30], whereas lower levels of BLyS are associated with antibody immunodeficiency [31], [32]. In addition, some human lymphoid tumors (non-Hodgkins lymphoma and multiple myeloma) may produce BLyS as an autocrine growth factor promoting tumor survival [33]-[35].
###end p 6
###begin p 7
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Gordon1">[22]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Kim1">[23]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Oren1">[36]</xref>
###xml 104 109 <span type="species:ncbi:9606">human</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 258 264 <span type="species:ncbi:10090">murine</span>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 391 397 <span type="species:ncbi:10090">murine</span>
Given the critical role of BLyS in normal B cell homeostasis, we proposed that the failure of efficient human B cell engraftment and survival in xenochimeras may be due to a BLyS deficiency. This failure could be due to species differences between human and murine BLyS that affect survival signaling. Consistent with this view, there is a single amino acid difference between the human and murine BLyS proteins in the portion of the molecule recognized by the BR3 receptor [18], [22], [23], [36].
###end p 7
###begin p 8
###xml 232 235 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 240 243 240 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 228 243 228 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag2<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 112 118 <span type="species:ncbi:10090">murine</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 279 284 <span type="species:ncbi:9606">human</span>
###xml 526 531 <span type="species:ncbi:9606">human</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
In this report, we show human recombinant BLyS improves human peripheral blood B cell survival in vitro whereas murine BLyS is ineffective. Moreover, engraftment of both B and T cells is markedly enhanced in immunodeficient NOD rag2-/- Prf1-/- mice supplemented with recombinant human BLyS. All B cell subpopulations are maintained, follicular-like structures develop and B cells secrete antibody and respond to challenge with thymus-independent pneumococcal antigens. Taken together, the data demonstrate the requirement for human BLyS for efficient engraftment of human B cells in immunodeficient mice.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 20 25 <span type="species:ncbi:9606">human</span>
Human BLyS enhances human B cell survival in vitro
###end title 10
###begin p 11
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 270 278 270 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">Figure 1</xref>
###xml 1098 1107 1098 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">Figure 1B</xref>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 130 135 <span type="species:ncbi:9606">human</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 187 193 <span type="species:ncbi:10090">murine</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
###xml 582 587 <span type="species:ncbi:9606">human</span>
###xml 854 859 <span type="species:ncbi:9606">human</span>
###xml 1039 1044 <span type="species:ncbi:9606">human</span>
###xml 1082 1088 <span type="species:ncbi:10090">murine</span>
###xml 1114 1119 <span type="species:ncbi:9606">human</span>
###xml 1124 1130 <span type="species:ncbi:10090">murine</span>
###xml 1173 1179 <span type="species:ncbi:10090">murine</span>
To establish possible species restrictions on BLyS dependent human B cell survival in vitro, CD19+ B cells from the PBL of normal human donors were cultured unstimulated or with human or murine BLyS and viability determined daily. The results from these determinations, Figure 1, clearly demonstrate that huBLyS enhances human B cell survival relative to either unstimulated or muBLyS supplemented cultures. Indeed, muBLyS provides no more survival advantage for human B cells than is seen in unstimulated cultures. Increasing the dose of muBLyS to 200 or 500 ng/ml did not improve human B cell survival (data not shown). Donor 1 was assayed on two separate occasions, 8 months apart, with similar results as indicated by the error bars in the graph. Statistical analysis of pooled data from 6 donors demonstrated the species dependence of BLyS mediated human B cell survival (at day 4 of culture: huBLyS vs. muBLyS, p = 0.0041; huBLyS vs unstimulated, p = 0.0014; muBLyS vs. unstimulated, p = ns). The species dependence of BLyS mediated human B cell survival was not observed for murine B cells, Figure 1B; both human and murine BLyS were equally effective at supporting murine B cell survival.
###end p 11
###begin title 12
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 55 61 <span type="species:ncbi:10090">murine</span>
In vitro survival of CD19+ human B cells with human or murine BLyS.
###end title 12
###begin p 13
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 166 171 <span type="species:ncbi:9606">human</span>
###xml 175 181 <span type="species:ncbi:10090">murine</span>
CD19+ B cells were purified from PBL by negative selection using RosetteSep kit and ficoll hypaque centrifugation. B cells were cultured for 4 days with 100 ng/ml of human or murine BLyS, cultures were resupplemented with BLyS on day 2. Viability was determined daily using cell counting with trypan blue and is represented as percentage of input cell number surviving. Donor 1 data is the average of 2 separate B cell preparations; donors 2-6 represent a single cell preparation. Statistical analysis for significance after 4 days in culture; huBLyS vs. muBLyS, p = 0.0041; huBLyS vs unstimulated, p = 0.0014; muBLyS vs. unstimulate, p = ns.
###end p 13
###begin p 14
###xml 375 376 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 382 383 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 389 390 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Cuss1">[37]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Sims1">[38]</xref>
###xml 700 708 700 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g002">Figure 2</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
To determine if huBLyS conferred a selective survival advantage to a particular subpopulation of PBL derived human B cells, input populations and cells remaining after 4 days of culture were compared by FACS using antibodies to CD19 (all B cells), CD27 (memory B), kappa and lambda light chains, CD10 (immature B), and CD38 (immature and plasma cells). Immature B cells (CD10+, CD27-, CD38+) represented 1-3% of input B cells from the various donors (our data and [37], [38]) and were undectable on day 4 analysis under all culture conditions. No other significant change in the character of the surviving B cell population relative to the input population as assessed by these markers was observed, Figure 2 data shown from CD19 and CD27 analysis.
###end p 14
###begin title 15
FACS analysis of B cell cultures.
###end title 15
###begin p 16
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 279 285 <span type="species:ncbi:10090">murine</span>
B cell populations were FACS analyzed for surface markers associated with resting B cells (CD45, CD19), memory cells (CD27), plasma cells (CD38) and kappa and lambda light chains on the day of isolation and after 4 days of culture either unstimulated or stimulated with human or murine BLyS. All samples were initially gated for lymphocytes by forward and side scatter. Data representative of 4 experiments.
###end p 16
###begin title 17
###xml 16 21 <span type="species:ncbi:9606">human</span>
muBLyS binds to human B cells but does not mobilize NF-kB p52 as effectively as huBLyS
###end title 17
###begin p 18
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Day1">[39]</xref>
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Thompson1">[40]</xref>
###xml 220 229 220 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g003">Figure 3A</xref>
###xml 550 554 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 556 560 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Claudio1">[19]</xref>
###xml 562 566 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Patke1">[41]</xref>
###xml 567 571 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Ramakrishnan1">[43]</xref>
###xml 754 758 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 760 764 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Claudio1">[19]</xref>
###xml 766 770 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Enzler1">[44]</xref>
###xml 801 809 785 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">Figure 1</xref>
###xml 1347 1356 1331 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g003">Figure 3B</xref>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 587 593 <span type="species:ncbi:10090">murine</span>
###xml 834 839 <span type="species:ncbi:9606">human</span>
Murine BLyS has been shown to bind to human BLyS receptors [39], [40]. When assayed by FACS, we find that human B cells bind both hu and mu BLyS, tested at the optimal concentration used in our survival assays (100 ng) (Figure 3A) and also at lower concentrations (1 and 10 ng, data not shown). These studies did not determine which of the BLyS receptors were occupied. BLyS signaling induces both the canonical (NF-kappaB1) and non-canonical (NF-kappaB2) pathways; activation of the non-canonical NF-kappaB2 pathway is important for B cell survival [18], [19], [41]-[43]. Studies using murine B cells have demonstrated that nuclear localization of NF-kappaB p52 is sustained for at least 48-72 hours following BLyS stimulation (laboratory observations; [18], [19], [44]). Our in vitro survival data (Figure 1) shows that by 48 hours human B cell survival in cultures supplemented with muBLyS is significantly lower (p = 0.008) than cultures supplemented with huBLyS, accordingly, we choose this time point to initially examine differences in nuclear localization of NF-kB p52. Western analysis of nuclear extracts prepared from cells after 48 hours of culture demonstrates that nuclear accumulation of NF-kB p52 in B cells stimulated with huBLyS was 3-fold higher than in B cells cultured with muBLyS and 7-fold higher than unstimulated B cells (Figure 3B, representative example). An analysis of p52 nuclear localization in three separate B cell preparations showed huBLyS induced on averaged 7.1+/-1.6 fold increase over unstimulated B cells verses an average 2.4+/-0.9 fold increase with muBLyS. While, muBLyS stimulation does result in higher nuclear accumulation of p52 compared to unstimulated B cells, this is insufficient to support in vitro B cell survival.
###end p 18
###begin title 19
Nuclear localization of NF-kappaB p52.
###end title 19
###begin p 20
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 372 377 <span type="species:ncbi:9606">human</span>
###xml 381 387 <span type="species:ncbi:10090">murine</span>
Purified CD19+ human B cells were A.) incubated with 100 ng/106 cells of FLAG-huBLyS or FLAG-muBLyS followed by biotinylated anti-FLAG and strep-avidin PerCP on the day of isolation prior to FACS analysis. Control stain with anti-FLAG and PerCP (dash/dot line); huBLyS (solid line) and muBLyS (dark dashed line) B.) B cells were cultured unstimulated or with 100 ng/ml of human or murine BLyS for 48 hours. Cells were harvested, nuclear extracts prepared and Western blots prepared following protein separation on a 4-12% SDS gel. Blots were probed with anti-p52 antibody then stripped and reprobed with anti-TATAbpalpha antibody. Blots were developed by ECL. Data representative of 3 separate expts.
###end p 20
###begin p 21
###xml 357 367 353 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003192.s001">figure S1A</xref>
###xml 449 457 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">figure 1</xref>
###xml 462 472 458 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003192.s001">figure S1A</xref>
###xml 761 770 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">figure 1B</xref>
###xml 120 126 <span type="species:ncbi:10090">murine</span>
###xml 255 261 <span type="species:ncbi:10090">murine</span>
###xml 425 431 <span type="species:ncbi:10090">murine</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
###xml 641 647 <span type="species:ncbi:10090">murine</span>
###xml 895 900 <span type="species:ncbi:9606">human</span>
To further investigate the notion that the amount of nuclear NF-kappaB p52 correlated with B cell survival, we cultured murine B cells with varying concentrations of huBLyS and assessed cell survival and p52 nuclear localization. We found the survival of murine B cells cultured with 1 ng/ml of huBLyS was similar to that observed in unstimulated cultures (figure S1A). In contrast, both 10 and 100 ng/ml of huBLyS supported murine B cell survival (figure 1 and figure S1A). After 48 hours of culture, nuclear extracts were made from all cultures, western blotted for NF-kappaB p52 and quantified. We observe that, similar to human B cells, murine B cells cultured with a sub-optimal huBLyS concentration mobilize low levels of p52 to the nucleus (supplemental figure 1B). It is noteworthy that the amount of nuclear p52 induced by the non-protective dose of huBLyS is similar to that seen with human cells cultured with 100 ng of muBLyS. Taken together, the data show a strong correlation between survival and the amount of p52 localized to the nucleus.
###end p 21
###begin title 22
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Engraftment of human B cells in immunodeficient mice
###end title 22
###begin p 23
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 156 159 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 152 165 152 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 362 370 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g004">Figure 4</xref>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 747 764 747 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g004">Figure 4, A and B</xref>
###xml 1026 1039 1026 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g004">Figure 4, C&#8211;E</xref>
###xml 1110 1118 1110 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g005">Figure 5</xref>
###xml 1144 1145 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1485 1494 1485 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g004">Figures 4</xref>
###xml 1499 1509 1499 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g005">5, D and E</xref>
###xml 1653 1662 1653 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g004">Figures 4</xref>
###xml 1667 1671 1667 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g005">5, C</xref>
###xml 1908 1915 1908 1915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 2067 2068 2067 2068 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2161 2165 2161 2165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Wagar1">[13]</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 472 477 <span type="species:ncbi:9606">human</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 890 895 <span type="species:ncbi:9606">human</span>
###xml 1274 1279 <span type="species:ncbi:9606">human</span>
###xml 1390 1394 <span type="species:ncbi:10090">mice</span>
###xml 1420 1425 <span type="species:ncbi:9606">human</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
###xml 2156 2160 <span type="species:ncbi:10090">mice</span>
To test whether huBLyS facilitated human B cell engraftment in immunodeficient mice, we transferred 20x106 human PBL by intrasplenic injection into NOD rag1-/-Ppf-/- mice. Recipients were given human recombinant BLyS (10 ug/mouse/day) or PBS i.p. for 7-14 days and sacrificed for analysis on day 21. Spleen samples were assessed by immunohistochemical staining. Figure 4 shows representative serial sections of spleens from PBS or BLys treated mice stained with H&E, anti-human CD45 and anti-human CD20. In PBS treated animals, the H&E staining shows relatively uniform reticular tissue, with few scattered CD45+ cells and no obvious formation of typical splenic architecture; importantly, cells staining with anti-CD20 were not readily observed (Figure 4, A and B). In marked contrast, BLyS treated mice showed a different morphology by H&E staining. Numerous follicle-like collections of human lymphocytes were observed and these stained strongly with anti-CD45 (both T and B cells) and with anti-CD20 (B cells) antibodies (Figure 4, C-E, CD45 and CD20). Higher magnification of the serial sections shown in Figure 5 clearly demonstrates CD45+ cells in areas not staining with CD20 suggesting the presence of T cells (see below). For comparison, we estimate the extent of human B cell engraftment by averaging the area of CD20+ staining cells within a number of microscopic fields. Among mice treated for 14 days with human BLyS, B cells comprise 30-50% of the spleen section areas (Figures 4 and 5, D and E), whereas, mice receiving BLyS for only 7 days generally had smaller areas of B cell engraftment, approximately 20-25% of the spleen sections (Figures 4 and 5, C). We evaluated the possibility that the marked B cell engraftment we observed was the result of an EBV-mediated lymphoproliferative disorder, however, the B cells in BLyS treated recipients were negative for EBV when examined by EBER-1 in situ hybridization (data not shown). This data is consistent with previous observations suggesting that three-fold higher numbers of PBL or depletion of CD8+ T cells are required for EBV-mediated lymphoproliferation in engrafted immunodeficient mice [13].
###end p 23
###begin title 24
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 50 65 50 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag2<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Immunohistology of in vivo PBL engraftment in NOD rag2-/- Prf1-/- mice.
###end title 24
###begin p 25
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 385 390 <span type="species:ncbi:10090">mouse</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
###xml 533 538 <span type="species:ncbi:9606">human</span>
On day of sacrifice, day 21 post PBL transfer, spleens were harvested and fixed for immunohistological analysis of B and T cell engraftment. Sections were visualized and photographed using a nikon microscope. All images were taken at 20x magnification. Rows A and B are PBS treated mice; C from mice treated 7 days with BLyS and, D and E from mice treated for 14 days with BLyS (10 ug/mouse/day). All mice were untreated days 14-21 prior to sacrifice. Serial sections were stained with hemotoxylin and eosin, anti-human CD45 or anti-human CD20. Data is representative of 6 experiments.
###end p 25
###begin title 26
Immunohistology.
###end title 26
###begin p 27
###xml 72 80 72 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g003">figure 3</xref>
Higher magnification images (100x) of portions of the sections shown in figure 3. Estimates of percentages of B cell engraftment are done at this magnification by comparing the percentage of the splenic section staining with anti-CD20.
###end p 27
###begin p 28
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 527 528 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 628 629 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 880 884 880 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Cabatingan1">[45]</xref>
###xml 885 889 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Woodland2">[47]</xref>
###xml 1313 1321 1313 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g006">Figure 6</xref>
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 331 336 <span type="species:ncbi:9606">Human</span>
###xml 548 553 <span type="species:ncbi:9606">human</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 1393 1397 <span type="species:ncbi:10090">mice</span>
###xml 1553 1558 <span type="species:ncbi:9606">human</span>
###xml 1616 1620 <span type="species:ncbi:10090">mice</span>
Whereas lymphocyte organization is revealed by immunohistology, more definitive quantitation of the human lymphocyte engraftment was assessed by flow cytometry. Spleens were divided in half upon harvest, with one half prepared for immunohistological analysis and the other prepared for FACS analysis by digestion with collagenase. Human lymphocyte yields (CD45+) from PBS treated recipients ranged between 0.27-5.8x106 cells/spleen, whereas, significantly more cells were isolated from recipients treated with BLyS (7.7-20.2x106 cells/spleen). The human B cell yields from the BLyS treated spleens was usually higher (4.1-9.5x106 cells/spleen) than the number of input B cells (2x106; 5-10% of total PBL) used to reconstitute the mice indicating that the engrafted cells had undergone proliferative expansion, perhaps by homeostatic proliferation induced by lymphocyte deficiency [45]-[47] or antigenic stimulation. Indeed, immunohistological staining of splenic sections with anti-Ki67, a marker for cells that have recently proliferated, was positive for almost all cells within the sections in BLyS-treated recipients whereas only scattered cells were positive in PBS-treated recipients (data not shown). Representative samples of collagenase disrupted spleens from separate experiments were analyzed by FACS (Figure 6) and showed that while T cells were present in some of the PBS treated mice (examples of positive engraftment shown with lymphocyte yield from test spleen), few, if any, B cells were detected in the same spleens. In contrast, both human B and T cells are readily detected in the huBLyS treated mice.
###end p 28
###begin title 29
FACS analysis of collagenase disrupted engrafted spleens.
###end title 29
###begin p 30
###xml 83 88 <span type="species:ncbi:9606">human</span>
One half of engrafted spleens were collagenase digested and then stained with anti-human CD45, CD20 and CD3 antibodies and analyzed by FACS. All samples were gated on live lymphocytes by forward and side scatter and then on CD45 positive cells. Data representative of 3 experiments. Total lymphocyte number = spleen cell countxpercentage of CD45+ cells.
###end p 30
###begin p 31
###xml 56 63 56 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003192-t001">Table 1</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 200 205 <span type="species:ncbi:9606">human</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 263 268 <span type="species:ncbi:9606">human</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
A summary of in vivo engraftment efficiency is shown in Table 1. Of the 16 mice treated with PBS, only 7 engrafted T cells and one of those 7 also engrafted B cells, overall 43% of the mice contained human lymphocytes. The PBS treated mice that were positive for human T or B cells had far fewer engrafted cells as determined by the sparse immunohistological staining; and reduced viable spleen cell yields. In comparison, 88% of the BLyS treated mice showed engraftment of both B and T cells with significantly higher numbers of donor splenocytes being isolated from these mice.
###end p 31
###begin title 32
Summary of in vivo engraftment data.
###end title 32
###begin p 33
###xml 71 74 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 67 82 67 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
Data from immunohistological analysis of splenic sections from NOD rag1-/- Prf1-/- mice receiving 20x106 PBL and then given 10 ug/mouse/day of huBLyS or PBS controls for 12-14 days and then sacrificed on day 21 post cell transfer. Sections were rated as positive if any CD45 or CD20 staining was observed at all.
###end p 33
###begin p 34
postitve sections as determined by immunohistological staining.
###end p 34
###begin title 35
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human BLyS is required for maintenance of the engrafted B cells
###end title 35
###begin p 36
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 80 93 80 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003192-t002">Table 2</xref>
###xml 1006 1013 1006 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003192-t002">Table 2</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
###xml 455 461 <span type="species:ncbi:10090">murine</span>
###xml 613 618 <span type="species:ncbi:10090">mouse</span>
###xml 668 673 <span type="species:ncbi:9606">human</span>
###xml 678 684 <span type="species:ncbi:10090">murine</span>
###xml 729 733 <span type="species:ncbi:10090">Mice</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
###xml 1163 1168 <span type="species:ncbi:9606">human</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
Human BLyS is required to initiate engraftment of B cells from human PBL in NOD rag1-/-Ppf-/- mice and we noted that mice receiving BLyS for only 7 days had lower amounts of B cells compared with mice receiving 14 days of treatment (20-25% vs 30-60%, determined by comparison of overall CD20 staining of histology sections, Table 2). To examine whether human B cells required the continued presence of huBLyS for in vivo survival as we would predict from murine B cell studies, a group of animals was treated for 7 days with huBLyS followed by injections of the soluble BLyS decoy receptor TACI-Ig protein (10 ug/mouse/day) for the next 7 days. TACI-Ig will bind both human and murine BLyS creating a BLyS deficient environment. Mice were sacrificed at day 21 and immunohistological analysis carried out on the spleens. We found that B cells were reduced when BLyS was withdrawn during PBS injections (about 2-fold lower) and were further reduced when mice received the BLyS decoy receptor (10-fold lower, Table 2, summary of histology results). Immunohistological analysis showed that T cells were still present (data not shown). Thus, maintenance of peripheral human B cell populations in reconstituted immunodeficient mice still require huBLyS.
###end p 36
###begin title 37
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 56 71 56 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
BLyS decoy receptor decreases B cell engraftment in NOD rag1-/- Prf1-/- mice.
###end title 37
###begin p 38
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 24 39 24 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 216 221 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
In two experiments, NOD rag1-/- Prf1-/- mice were given 20x106 PBL were injected i.p. for 7 days with 10 ug/day/mouse of huBLyS, then divided into 3 groups of 3 mice each, the 3 groups received either PBS, 10 ug/day/mouse of huBLyS or 10 ug/day/mouse of TACI-Ig for 7 more days. Animals were sacrificed on day 21 and spleens analyzed by immunohistochemistry. Percentage of B cell engraftment was determined by analysis of the percentage of splenic sections staining with anti-CD20 and by FACS analysis of collagenase disrupted spleen samples.
###end p 38
###begin title 39
In vivo antibody production
###end title 39
###begin p 40
###xml 157 160 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 163 166 163 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 153 166 153 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 543 550 543 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003192-t003">Table 3</xref>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">Mice</span>
To determine if the B cells in recipient mice were functional, we assessed human antibody production in mice treated with PBS or huBLyS for 14 days. NOD rag1-/-Ppf-/- mouse serum had undetectable levels of antibody. PBS treated recipients averaged 5 ug/ml of IgM and 60 ug/ml of IgG suggesting some early activation of transferred B cells prior to their loss from the animals. Recipients treated 14 days with BLyS had 40 fold more IgM, average 200 ug/ml, and 10 fold more IgG, 570 ug/ml consistent with the levels of B cell engraftment found (Table 3). To determine if antibody production was sensitive to BLyS depletion, mice were treated for 7 days with BLyS or 7 days with BLyS and then 7 days of TACI-Ig decoy receptor. Mice treated with TACI-Ig had approximately 8-fold lower amounts of IgM, 28 ug/ml, and 2-fold lower IgG compared to recipients receiving 14 days of BLyS treatment; consistent with TACI-Ig depletion of B cells and with the different half-lives of the antibody classes.
###end p 40
###begin title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human serum Ig.
###end title 41
###begin p 42
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Serum was collected at the time of sacrifice, day 21, and analyzed for human IgM and IgG synthesis from PBL engrafted mice treated for 14 days with PBS or BLyS, 7 days with BLyS, or 7 days with BLyS followed by 7 days of TACI-Ig. Data is representative of 3 experiments.
###end p 42
###begin p 43
ND, none detected, below the 3 ng sensitivity of the assays.
###end p 43
###begin p 44
###xml 367 374 367 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003192-t004">Table 4</xref>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 391 415 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 965 970 <span type="species:ncbi:9606">human</span>
To assess the antigen responsiveness of transferred B cells, PBL recipients were immunized with pneumovax23, to test whether engrafted B cells could produce a de novo antibody response to a thymus-independent type 2 antigen. Recipient mice were vaccinated on the day of PBL transfer and serum collected at day 21 and analyzed with a serotype specific ELISA. Shown in Table 4 is the data for Streptococcus pneumoniae serotype 14, one of the 23 pneumococcal polysaccharide strains in the vaccine. Serum from PBL engrafted mice receiving PBS, huBLyS or PBS plus vaccine had a similar low quantity of anti-polysaccharide antibody, ranged between 0.7-1.4 ng/ml for IgM and 2.4-3.3 ng/ml for IgG. In striking contrast, recipients of huBLyS and vaccine averaged 10-fold higher amounts, 9 ng/ml IgM and 45 ng/ml IgG, of serotype 14 specific antibody. Similar levels of IgG and IgM were observed for pneumococcal serotype 4 (data not shown). These data demonstrate that the human B cells in PBL recipients can respond de novo to challenge with T cell independent antigens.
###end p 44
###begin title 45
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 77 92 77 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup> Prf1<sup>&#8722;/&#8722;</sup></italic>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Induction of a thymus-independent immune response in human PBL engrafted NOD rag1-/- Prf1-/- mice.
###end title 45
###begin p 46
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 166 190 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
PBL recipient mice were immunized with 20 ul/mouse pneumovax23 s.c. on the day of cell transfer. Serum was harvested on the day of sacrifice and assayed by ELISA for Streptococcus pneumoniae serotype 14 specific antibodies. Data representative of two experiments.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 114 117 114 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 110 123 110 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 290 293 290 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 280 293 280 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Tavernier1">[48]</xref>
###xml 615 619 615 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Kumar1">[52]</xref>
###xml 858 862 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Bossen1">[18]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Gordon1">[22]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Kim1">[23]</xref>
###xml 876 880 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Smirnova1">[53]</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 258 264 <span type="species:ncbi:10090">murine</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 386 392 <span type="species:ncbi:10090">murine</span>
###xml 662 668 <span type="species:ncbi:10090">murine</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
###xml 844 849 <span type="species:ncbi:9606">human</span>
###xml 991 996 <span type="species:ncbi:9606">human</span>
These experiments demonstrate the requirement for human BLyS to efficiently reconstitute human B cells in NOD rag1-/-Ppf-/- immunodeficient mice. A species specific BLyS restriction is demonstrated for human B cells in culture and for B cells transferred to murine hosts. The NOD rag1-/-Ppf-/- environment is not BLyS deficient, per se, as these mice readily support the engraftment of murine B cells. Species specificity in the action of survival and growth promoting cytokines is not novel to members of the TNF family; IL-2, IL-5, IL-6, and gamma interferon have all demonstrated species restrictions [18], [48]-[52]. Moreover, amino acid differences between murine and human BLyS in the BR3 receptor binding region and/or differences in the BLyS binding region of the BR3 receptor are known to have marked effects on survival signaling for human B cells [18], [22], [23], [53]. While we favor the notion that the basis for species restriction is in the interaction between BLyS and BR3, human B and T cells also express the TACI receptor for BLyS and differences in huBLyS and muBLyS binding to and signaling through TACI may also contribute to our results.
###end p 48
###begin p 49
###xml 451 455 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Claudio1">[19]</xref>
###xml 457 461 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Enzler1">[44]</xref>
###xml 1050 1058 1042 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003192-g001">figure 1</xref>
###xml 1153 1157 1145 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Woodland3">[54]</xref>
###xml 10 15 <span type="species:ncbi:9606">human</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 83 89 <span type="species:ncbi:10090">murine</span>
###xml 167 172 <span type="species:ncbi:9606">human</span>
###xml 177 183 <span type="species:ncbi:10090">murine</span>
###xml 250 256 <span type="species:ncbi:10090">murine</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
###xml 518 524 <span type="species:ncbi:10090">murine</span>
###xml 548 553 <span type="species:ncbi:9606">human</span>
###xml 588 593 <span type="species:ncbi:9606">human</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
###xml 661 667 <span type="species:ncbi:10090">murine</span>
###xml 859 864 <span type="species:ncbi:9606">human</span>
###xml 912 917 <span type="species:ncbi:9606">human</span>
###xml 926 932 <span type="species:ncbi:10090">murine</span>
###xml 1138 1144 <span type="species:ncbi:10090">murine</span>
###xml 1226 1231 <span type="species:ncbi:9606">human</span>
In vitro, human BLyS supported significantly better human B cell survival than did murine BLyS, which was indistinguishable from unsupplemented cultures. In contrast, human and murine BLyS were equally effective at promoting the in vitro survival of murine B cells. Concurrent with the survival effect, BLyS stimulation leads to a prolonged induction of NF-kappaB p100 processing and nuclear localization of NF-kappaB p52 (laboratory observations and [19], [44]). While freshly isolated human B cells bind FLAG-tagged murine BLyS as efficiently as human BLyS, p52 nuclear localization in human B cells induced by human BLyS was more robust than that induced by murine BLyS. This shows a dissociation between BLyS binding and survival signaling which may be the result of a species difference in the binding requirement for activation of BR3/TACI receptors on human B cells. It is noteworthy that in titration of human BLyS on murine B cells diminished B cell survival was correlated directly with the extent of p52 nuclear localization (supplemental figure 1). Our laboratory has recently defined the survival pathways induced by BLyS in murine B cells [54] and further experiments are in progress to define these pathways in human B cells.
###end p 49
###begin p 50
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 64 77 64 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Shultz3">[10]</xref>
###xml 700 704 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Wagar1">[13]</xref>
###xml 706 710 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Depraetere1">[55]</xref>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Cao1">[60]</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 90 95 <span type="species:ncbi:9606">Human</span>
###xml 267 272 <span type="species:ncbi:9606">human</span>
###xml 277 283 <span type="species:ncbi:10090">murine</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
Engraftment of human B cells is efficient in huBLyS treated NOD rag1-/-Ppf-/- recipients. Human BLyS is continually required to maintain the B cells over the 3 week period used in these studies since treatment with a BLyS decoy receptor, TACI-Ig, which depletes both human and murine BLyS from the animals, resulted in loss of B cells as assessed by immunohistological analysis and resulted in lower serum IgM and IgG compared with mice treated for 14 days with BLyS. Our engraftment data using huBLyS supplementation contrasts from that observed in other PBL xenochimera models where few, if any, human B cells are observed after cell transfer and those B cells do not survive beyond one week [10], [13], [55]-[60].
###end p 50
###begin p 51
###xml 358 362 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Cabatingan1">[45]</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Agenes1">[61]</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Freitas1">[62]</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 153 158 <span type="species:ncbi:9606">Human</span>
###xml 292 298 <span type="species:ncbi:10090">murine</span>
###xml 580 585 <span type="species:ncbi:9606">human</span>
The B cells are functional as we find significantly higher amounts of human IgM and IgG in chimeras receiving huBLyS compared with PBS treated controls. Human Ig production could result from the homeostatic activation of naive or memory B cells. Homeostatic B cell proliferation is seen when murine B cells are transferred into B cell deficient environments [45], [61], [62], however this mechanism has not been evaluate in xenochimeras. It is also possible that activation by xenoantigens can contribute to B cell activation and serum Ig. The antigen responsiveness of engrafted human B cells and the ability to induce a de novo immune response is demonstrated by the production of anti-pneumococcal antibodies following immunization with the thymus-independent antigens in pneumovax23. There was a 10-20 fold increase, respectively in IgM and IgG, in pneumococcal antibodies in BLyS treated recipients compared to BLyS treated and unimmunized and PBS treated immunized controls. This xenochimera model with enhanced B cell engraftment provides a unique opportunity to test vaccine responses using PBL samples from a variety of individuals, including neonates and the aged who frequently exhibit weak immune responsiveness.
###end p 51
###begin p 52
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Mackay3">[63]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Ye1">[66]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Cabatingan1">[45]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Woodland1">[46]</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Prlic1">[67]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Marleau1">[69]</xref>
###xml 805 809 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Mackay3">[63]</xref>
###xml 1217 1218 1217 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1227 1231 1227 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-DiazdeDurana1">[70]</xref>
###xml 1265 1266 1265 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1288 1292 1288 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Ye1">[66]</xref>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 279 284 <span type="species:ncbi:9606">human</span>
###xml 811 816 <span type="species:ncbi:9606">Human</span>
###xml 876 882 <span type="species:ncbi:10090">murine</span>
###xml 979 984 <span type="species:ncbi:9606">human</span>
###xml 1482 1487 <span type="species:ncbi:9606">human</span>
###xml 1554 1559 <span type="species:ncbi:9606">human</span>
###xml 1607 1612 <span type="species:ncbi:9606">human</span>
###xml 1625 1630 <span type="species:ncbi:9606">human</span>
###xml 1675 1680 <span type="species:ncbi:9606">human</span>
Immunohistological analysis of recipient mice receiving only PBS revealed only scattered human T cells but these cells were readily identified by FACS analysis of collagenase digested spleens. It was noted, however, that there was a marked improvement of T cell engraftment with human BLyS supplementation. Both T and B cell yields from BLyS treated recipients was much higher than that observed with PBS treated recipients. Recent publications demonstrate that BLyS can act as a co-stimulator for T cells acting through BR3 and/or TACI [63]-[66]. T cells, like B cells, will under go homeostatic proliferation when introduced to a T cell deficient environment [45], [46], [67]-[69]. This proliferation causes induction of early activation markers, including expression of BR3 mRNA and protein on T cells [63]. Human T cells may also undergo activation to xenoantigens in the murine environment, again upregulating the BLyS receptor. In this regard, it is also possible that the human B cells themselves can present antigen to the T cells, thereby facilitating T cell expansion and survival. TACI-BLyS signaling in B cell-dendritic cell interactions have been shown to increase the expansion of antigen responsive CD8+ T cells [70] whereas BR3-BLyS costimulates CD4+ T cell alloresponses [66]. We did note that use of the TACI decoy receptor in vivo resulted in loss of both B and T cells, although B cells were affected to a greater degree. Taken together, these data suggest that human T cell engraftment may also be enhanced directly or indirectly by human BLyS treatment. Further studies using purified human T cells and human BLyS supplementation should address whether human BLyS acts directly on T cells to facilitate engraftment.
###end p 52
###begin p 53
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Shultz1">[1]</xref>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-King1">[71]</xref>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Mackay3">[63]</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Ng1">[65]</xref>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 500 506 <span type="species:ncbi:10090">murine</span>
Since huBLyS enhances engraftment of both B and T cells, we considered the possibility that prolonged exposure to huBLyS may increase the rate of graft verses host disease (GVH) in the PBL recipient mice. No GVH was seen by observation or histological analysis at the 3 week time points assessed in these experiments even in recipients with the robust B and T cell engraftment, however, other investigators have found evidence of GVH by 4-6 weeks post-PBL engraftment in a variety of immunodeficient murine hosts [1], [71]. Regulatory T cells have recently been shown to express BLyS receptors and it is possible that huBLyS treated animals engraft sufficient regulatory cells to delay or prevent GVH [63], [65].
###end p 53
###begin p 54
###xml 29 34 <span type="species:ncbi:9606">human</span>
Our data suggest recombinant human BLyS has a significant enhancing effect on the engraftment of both T and B cell populations in PBL.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human lymphocytes
###end title 56
###begin p 57
###xml 402 403 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">Human</span>
Human blood was obtained from healthy volunteers and blood donors under signed consent in accordance with the Declaration of Helsinki and approval from the Institutional Review Board of the University of Massachusetts Medical School. Total human peripheral blood mononuclear cells (PBL) were purified by Ficoll gradient separation, quantified and viability assessed by trypan blue exclusion. Human CD19+ B cells were purified from PBL by negative selection using RosetteSep (StemCell Technologies, Vancouver BC, Canada).
###end p 57
###begin title 58
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine lymphocytes
###end title 58
###begin p 59
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Woodland4">[72]</xref>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine B cells were prepared by anti-thy1.2 and complement treatment of splenocytes followed by purification of resting B cells using a step percoll gradient harvesting cells at the 60-70% interface [72].
###end p 59
###begin title 60
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 60
###begin p 61
###xml 11 17 11 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Mom</sup>
###xml 20 27 20 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Sclz</sup>
###xml 7 27 7 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>tm1Mom</sup>Ppf<sup>tm1Sclz</sup></italic>
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 49 62 49 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 160 164 <span type="species:ncbi:10090">Mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
NOD/Cg-Rag1tm1MomPpftm1Sclz/SzJ (abbreviated NOD rag1-/-Ppf-/-, stock # 004848) and C57BL/6 mice were obtained from Jackson Laboratories and NCI, respectively. Mice were housed at the University of Massachusetts Medical School under specific pathogen free conditions in accordance with federal and institutional IACUC guidelines. Immunodeficient mice received acidified (HCl; pH 2.8-3.2) water containing trimethoprim-sulfamethoxazole (Goldline Laboratories, Ft. Lauderdale, FL) ad librium for 7 consecutive days every other week.
###end p 61
###begin title 62
BLyS
###end title 62
###begin p 63
###xml 937 940 937 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 99 104 <span type="species:ncbi:9606">Human</span>
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 1010 1015 <span type="species:ncbi:9606">human</span>
###xml 1191 1197 <span type="species:ncbi:10090">murine</span>
Two sources of human BLyS were used in these experiments. Purified recombinant human BLyS (huBLyS, Human Genome Sciences, Rockville, MD 20850) or recombinant human FLAG-tagged BLyS (FL-BLyS) purified in our laboratory from transfected CHO cell supernant (cell line generously provided by Dr. Randolph Noelle, Dartmouth Univ. Lebanon, NH). Briefly, stably transfected CHO cells were grown in DMEM (7%FCS, 2 mM glutamine, 1x MEM non-essential amino acids, 10 units/ml penicillin and 10 ug/ml streptomycin) and supernatants collected. Supernatants were dialyzed against 50 mMTris pH 8.0, 50 mM NaCl, 0.02% sodium azide prior to running over an anti-FLAG M2 agarose column (Sigma-Aldrich Biochemicals). FL-BLyS was eluted with 0.1 M glycine HCl pH 3.0 and dialyzed against PBS, incubated with polymyxin B-agarose beads (Sigma-Aldrich, 1 ml of 50% suspension per 15 mls) for I hour, sterile filtered and quantitated by spectrophotometry (1 OD280 = 1.15 mg/ml). Purity was assessed by SDS-PAGE and Western blot. All human BLyS preparations tested negative for endotoxin and mycoplasma. Both huBLyS and FL-BLyS performed equivalently and were used interchangeably in these experiments. FLAG-tagged murine BLyS (muBLyS) (#522-052-C010) was obtained from Alexis biochemicals (Axxora, San Diego, CA 92121).
###end p 63
###begin title 64
Cell culture
###end title 64
###begin p 65
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 308 314 <span type="species:ncbi:10090">murine</span>
###xml 769 774 <span type="species:ncbi:9606">human</span>
Purified CD19+ B cells (94-98% pure by FACS analysis) were cultured at 5x106 cells per ml in RPMI 1640 - complete media (CM: 10% FCS, 2 mM glutamine, 1x non-essential DMEM amino acids, 10 units/ml penicilin, 1 ug/ml streptomycin, 5x10-5 M 2-mercaptoethanol) alone or in the presence of 100 ng/ml of human or murine BLyS for 4 days. Preliminary experiments established the dose of BLyS sufficient for optimal cell survival: 1, 10, 100, 250 and 500 ng/ml were tested and no significant differences on cell survival were found at doses of 10 ng/ml or greater. BLyS was readded to the cultures on day 2. Cell survival was determined by counting daily using trypan blue exclusion for viability. Input populations and cells remaining after 4 days of culture were stained for human CD19, CD27, CD38, CD10, kappa and lambda light chains and analyzed by FACS.
###end p 65
###begin title 66
In vivo engraftment
###end title 66
###begin p 67
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 35 48 35 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rag1<sup>&#8722;/&#8722;</sup>Ppf<sup>&#8722;/&#8722;</sup></italic>
###xml 242 243 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 184 189 <span type="species:ncbi:9606">human</span>
In preparation for engraftment NOD rag1-/-Ppf-/- received a single i.p. injection of 1.0 mg of TMbeta1 (anti-CD122) monoclonal antibody for depletion of NK cells and 10 ug of purified human recombinant BLyS (huBLyS). Recipients received 20x106 PBL by intrasplenic injection followed by daily i.p. injection of 10 ug huBLyS or endotoxin free PBS for 7-14 days. Spleens were harvested 14-21 days post PBL transfer and processed for immunohistochemisry. In some expts, spleens were bisected and each half processed for either immunohistochemistry or FACS analysis.
###end p 67
###begin title 68
Decoy receptor
###end title 68
###begin p 69
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
###xml 139 144 <span type="species:ncbi:9606">Human</span>
To deplete BLyS in vivo, groups of 3 mice that had previously received huBLyS for 7 days were given soluble TACI-Ig (10 ug i.p./mouse/day, Human Genome Sciences) for 7 subsequent days.
###end p 69
###begin title 70
Antibodies
###end title 70
###begin p 71
###xml 16 21 <span type="species:ncbi:9606">human</span>
Sources of anti-human antibodies used for FACS staining. Caltag: CD3-FITC, CD45-APC, CD45-PE, CD20-APC, CD19-APC, CD19-PE, IgD-FITC, CD38-PE; ebioscience: CD27-FITC, CD138-FITC and PE, CD10-biotin, kappa-biotin, lambda-biotin: BD Pharmingen: streptavidin-PerCP, IgM-APC, and CD45-PECy5.5. For immunohistochemistry BD Pharmingen: CD45, CD3, CD20, Ki67, and EBNA1.
###end p 71
###begin title 72
Immunohistochemistry
###end title 72
###begin p 73
###xml 172 177 <span type="species:ncbi:9606">human</span>
###xml 522 526 <span type="species:ncbi:9925">goat</span>
###xml 532 538 <span type="species:ncbi:9986">rabbit</span>
###xml 545 549 <span type="species:ncbi:9925">goat</span>
###xml 555 560 <span type="species:ncbi:10090">mouse</span>
###xml 568 579 <span type="species:ncbi:3704">horseradish</span>
At sacrifice, spleens were fixed in 10% neutral buffered formalin, embedded in paraffin, and 5 um tissue sections were cut. Immunohistochemical staining was performed with human specific mABs (BD Pharmingen, San Diego, CA). Prior to staining sections were incubated in 0.1 M citrate buffer (pH 6.0) for 15 mins and then stained on a Dako (Carpinteria, CA) automated immunostainer using the EnVision (Dako) staining procedure. The sections were incubated with the EnVision plus Dual Link reagent (a polymer conjugated with goat anti-rabbit Ig or goat anti-mouse Ig and horseradish peroxidase) for 30 min. The sections were washed and reacted with 3-diaminobenzidine and hydrogen peroxide and counterstained with hemotoxylin for visualization by light microscopy.
###end p 73
###begin title 74
Flow cytometry
###end title 74
###begin p 75
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 850 851 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 977 978 965 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 333 339 <span type="species:ncbi:10090">murine</span>
###xml 343 348 <span type="species:ncbi:9606">human</span>
###xml 472 477 <span type="species:ncbi:9606">human</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 1079 1085 <span type="species:ncbi:9986">rabbit</span>
###xml 1090 1095 <span type="species:ncbi:10090">mouse</span>
###xml 1126 1131 <span type="species:ncbi:10090">mouse</span>
###xml 1459 1464 <span type="species:ncbi:9606">human</span>
For in vitro experiments, purified PBL B cells were tested for purity and subpopulations characterized after initial isolation and 4 days of culture using CD45, CD19, CD20, CD27 and CD38 antibodies conjugated with APC, Fitc, PE or PerCp, described below. BLyS binding was determined by incubating 106 purified B cells with 100 ng of murine or human FL-BLyS, followed by biotinylated anti-FLAG antibody (#F9291, SigmaAldrich) and strept-avidin PerCP (BD). FACS analysis of human lymphocyte engrafted mice was performed as follows: half of each recipient spleen was minced and incubated in 0.5ml HBSS containing 2.4 mg/ml collagenase XI (SigmaAldrich), 1 mg/ml DNAse I and 2% FCS for one hour at 37degreesC in a shaking water bath. Cell suspensions were then washed twice with CM, resuspended in 1 ml CM and incubated for one hour at 37degreesC in a CO2 incubator prior to FACS staining. Single cell suspensions were washed into FACS buffer (PBS, 3%FCS, 0.02% sodium azide) and106 cells in 100 ul kept on ice for staining. Nonspecific staining was blocked by incubating cells with rabbit and mouse IgG (3ug) or 10 ul of C57BL/6 mouse serum for 10 mins on ice prior to adding fluorchrome-labeled antibodies. Cells were stained for 30-45 mins, washed and fixed with 2% paraformaldehyde prior to analysis. Engrafted cell numbers were determined from total cell counts isolated by collagenase multiplied by 2 (half of each spleen digested) and by the percentage of human CD45+ cells. Samples were analyzed using BD FACScalibur or FACSVantage machines and data analyzed using FlowJo software (Tree Star Inc., Ashland, OR).
###end p 75
###begin title 76
Western blotting
###end title 76
###begin p 77
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003192-Tam1">[73]</xref>
###xml 743 747 <span type="species:ncbi:9925">goat</span>
###xml 753 759 <span type="species:ncbi:9986">rabbit</span>
Purified CD19+ B cells were cultured unstimulated or with 100 ng/ml of mu FL-BLyS or hu FL-BLyS for 48 hours. Cells were harvested and nuclear and cytoplasmic extracts prepared as described [73]. Protein content was determined using Commassie protein assay reagent (Pierce Biotechnology, Rockland, IL) Samples were run on 4-12% NuPAGE MOPS gels (Invitrogen) and transferred to nitrocellulose membrane overnight. Membranes were blocked with 5% BSA, PBS, 0.2% Tween-20 buffer, anti-p100/p52 antibody (#4882, Cell Signaling Technology, Danvers, MA) or TATA binding protien (#AB818, Abcam, Cambridge Science Park, UK) as nuclear loading control added and incubated overnight at 4degreesC. Filters were washed with PBS+0.2%Tween-20, incubated with goat anti-rabbit HRP (Cell Signaling Technology), washed and developed using Amersham ECL plus detection system. Quantitation of signal was performed using a Molecular Dynamics Densitometer and BioRad Multi-analyst software.
###end p 77
###begin title 78
Determination of serum Ig
###end title 78
###begin p 79
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 193 197 <span type="species:ncbi:9925">goat</span>
###xml 203 208 <span type="species:ncbi:9606">human</span>
###xml 421 426 <span type="species:ncbi:9606">human</span>
To assess polyclonal Ig production, sera were collected from cell recipients at the time of sacrifice and assayed for human Ig by ELISA. ELISA plates were coated overnight with 3 ug/ml F(ab')2 goat anti-human IgG or IgM (Jackson Immunologicals) in PBS, 100 ul/well. Plates were washed with PBS, blocked for one hour with 0.5% BSA in PBS and serum dilutions added and incubated 1-2 hours. After washing, biotinylated anti-human kappa and/or lambda antibodies were added followed by washing and addition of streptavidin-HRP. The assay was developed with tetramethylbenzidine dihydrochloride (Sigma-Aldrich), stopped with sulfuric acid and read at 450 nm. Limits of detection were 3 ng/ml for IgM and 2 ng/ml for IgG.
###end p 79
###begin title 80
Immunizations
###end title 80
###begin p 81
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
In two experiments, engrafted mice were immunized with pneumovax 23 (Merck, Whitehouse Station, NJ), 20 ul/mouse s.c. (containing 1 ug of each of 23 pneumococcal serotypes) on the day of cell transfer.
###end p 81
###begin title 82
Pneumovax ELISA
###end title 82
###begin p 83
###xml 1137 1140 1131 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">405</sub>
###xml 1143 1146 1137 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">690</sub>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 728 733 <span type="species:ncbi:9606">human</span>
###xml 753 758 <span type="species:ncbi:9606">human</span>
Immune responses to pneumovax23 were examined for 2 of the 23 pneumococcal serotypes, 4 and 14 (Danish strain designation) in the vaccine. ELISA analysis was performed according to WHO protocol (). Briefly, polystyrene ELISA plates were coated with 100 ul of 1 ug/ml serotype specific polysaccharides (type 4, ATCC #18-X and type 14, ATCC #23-X) for 5 hours at 37degreesC. Control human serum (89SF-2, US reference standard generously provided by Dr. Carl Frasch, CBER/FDA, Rockville, MD) with known concentrations of IgG and IgM to each serotype was used as a standard. Control serum and serial dilutions of unknowns were added to the plates, incubated overnight at room temperature. Plates were washed and incubated with anti-human IgG biotin or anti-human IgM biotin (#2040-08 and #2020-08, respectively, Southern Biotech, Birmingham, AL) for 2 hours, washed and strep-avidin-alkaline phosphatase (Southern Biotech) added for 1 hour. After washing the assay was developed with 1 mg/ml p-nitrophenyl phosphate in diethanolamine substrate for 2 hours, fixed with 3 M NaOH and read at OD 405 nm and 690 nm. Concentration determined as OD405-OD690 and read off the standard curve.
###end p 83
###begin title 84
Supporting Information
###end title 84
###begin p 85
(0.15 MB TIF)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
###xml 97 102 <span type="species:ncbi:9606">Human</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
We thank Sarah Kenward, Jean Leif and Linda Paquin for their technical assistance. We also thank Human Genome Sciences for providing recombinant human BLyS.
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
###xml 10 14 <span type="species:ncbi:10090">mice</span>
Humanized mice in translational biomedical research.
###end article-title 89
###begin article-title 90
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 29 33 <span type="species:ncbi:10090">Mice</span>
Human-Hemato-Lymphoid-System Mice: Opportunities and Challenges.
###end article-title 90
###begin article-title 91
###xml 10 14 <span type="species:ncbi:10090">mice</span>
Humanized mice: are we there yet?
###end article-title 91
###begin article-title 92
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice.
###end article-title 92
###begin article-title 93
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain.
###end article-title 93
###begin article-title 94
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model.
###end article-title 94
###begin article-title 95
###xml 99 104 <span type="species:ncbi:9606">human</span>
Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells.
###end article-title 95
###begin article-title 96
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Appearance of human plasma cells following differentiation of human B cells in NOD/SCID mouse spleen.
###end article-title 96
###begin article-title 97
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 115 118 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells.
###end article-title 97
###begin article-title 98
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment.
###end article-title 98
###begin article-title 99
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Development of a human adaptive immune system in cord blood cell-transplanted mice.
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 77 81 <span type="species:ncbi:10090">Mice</span>
###xml 107 112 <span type="species:ncbi:9606">Human</span>
Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2R{gamma}null Mice Engrafted with Mobilized Human Hemopoietic Stem Cells.
###end article-title 100
###begin article-title 101
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
###end article-title 101
###begin article-title 102
Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.
###end article-title 102
###begin article-title 103
BAFF: a fundamental survival factor for B cells.
###end article-title 103
###begin article-title 104
BAFF AND APRIL: a tutorial on B cell survival.
###end article-title 104
###begin article-title 105
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
BAFF is a survival and maturation factor for mouse B cells.
###end article-title 105
###begin article-title 106
BAFF, APRIL and their receptors: structure, function and signaling.
###end article-title 106
###begin article-title 107
BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.
###end article-title 107
###begin article-title 108
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation.
###end article-title 108
###begin article-title 109
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology.
###end article-title 109
###begin article-title 110
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.
###end article-title 110
###begin article-title 111
Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.
###end article-title 111
###begin article-title 112
BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex.
###end article-title 112
###begin article-title 113
B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation.
###end article-title 113
###begin article-title 114
###xml 14 19 <span type="species:ncbi:9606">human</span>
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors.
###end article-title 114
###begin article-title 115
###xml 70 75 <span type="species:ncbi:9606">human</span>
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.
###end article-title 115
###begin article-title 116
B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.
###end article-title 116
###begin article-title 117
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels.
###end article-title 117
###begin article-title 118
Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases.
###end article-title 118
###begin article-title 119
B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro.
###end article-title 119
###begin article-title 120
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Mutational analysis of human BLyS in patients with common variable immunodeficiency.
###end article-title 120
###begin article-title 121
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
###end article-title 121
###begin article-title 122
BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target.
###end article-title 122
###begin article-title 123
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
###end article-title 123
###begin article-title 124
Structural basis of BLyS receptor recognition.
###end article-title 124
###begin article-title 125
###xml 75 80 <span type="species:ncbi:9606">human</span>
Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity.
###end article-title 125
###begin article-title 126
###xml 51 56 <span type="species:ncbi:9606">human</span>
Identification and characterization of circulating human transitional B cells.
###end article-title 126
###begin article-title 127
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
###end article-title 127
###begin article-title 128
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population.
###end article-title 128
###begin article-title 129
Survival signaling in resting B cells.
###end article-title 129
###begin article-title 130
BLyS binds to B cells with high affinity and induces activation of the transcription factors NF-kappaB and ELF-1.
###end article-title 130
###begin article-title 131
Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase.
###end article-title 131
###begin article-title 132
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease.
###end article-title 132
###begin article-title 133
Naive B lymphocytes undergo homeostatic proliferation in response to B cell deficit.
###end article-title 133
###begin article-title 134
Homeostatic proliferation of B cells.
###end article-title 134
###begin article-title 135
BLyS and B cell homeostasis.
###end article-title 135
###begin article-title 136
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 24 30 <span type="species:ncbi:10090">murine</span>
Expression of human and murine interleukin-5 in eukaryotic systems.
###end article-title 136
###begin article-title 137
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Structure-function analysis of interleukin-5 utilizing mouse/human chimeric molecules.
###end article-title 137
###begin article-title 138
Characterization of accessory cell costimulation of Th1 cytokine synthesis.
###end article-title 138
###begin article-title 139
###xml 36 42 <span type="species:ncbi:9913">bovine</span>
Biological functions of recombinant bovine interleukin 6 expressed in a baculovirus system.
###end article-title 139
###begin article-title 140
###xml 34 40 <span type="species:ncbi:10090">murine</span>
Molecular characterization of the murine interferon gamma receptor cDNA.
###end article-title 140
###begin article-title 141
Identification of new splice variants of the genes BAFF and BCMA.
###end article-title 141
###begin article-title 142
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.
###end article-title 142
###begin article-title 143
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Human B cell growth and differentiation in the spleen of immunodeficient mice.
###end article-title 143
###begin article-title 144
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.
###end article-title 144
###begin article-title 145
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice.
###end article-title 145
###begin article-title 146
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.
###end article-title 146
###begin article-title 147
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes.
###end article-title 147
###begin article-title 148
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.
###end article-title 148
###begin article-title 149
Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population.
###end article-title 149
###begin article-title 150
Population biology of lymphocytes: the flight for survival.
###end article-title 150
###begin article-title 151
The role of the BAFF/APRIL system on T cell function.
###end article-title 151
###begin article-title 152
T cell costimulation by the TNF ligand BAFF.
###end article-title 152
###begin article-title 153
The BAFF/APRIL system: life beyond B lymphocytes.
###end article-title 153
###begin article-title 154
BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses.
###end article-title 154
###begin article-title 155
Homeostatic expansion versus antigen-driven proliferation: common ends by different means?
###end article-title 155
###begin article-title 156
The molecular program induced in T cells undergoing homeostatic proliferation.
###end article-title 156
###begin article-title 157
T cell homeostasis in tolerance and immunity.
###end article-title 157
###begin article-title 158
TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo.
###end article-title 158
###begin article-title 159
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
###end article-title 159
###begin article-title 160
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Regulation of B cell survival in xid mice by the proto-oncogene bcl-2.
###end article-title 160
###begin article-title 161
Cell-specific association and shuttling of IkappaBalpha provides a mechanism for nuclear NF-kappaB in B lymphocytes.
###end article-title 161
###begin p 162
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 162
###begin p 163
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 312 317 <span type="species:ncbi:9606">Human</span>
###xml 343 348 <span type="species:ncbi:9606">human</span>
Funding: This work was supported by National Institutes of Health Grants AI 041054, AI57463, HL77642, AI46629, an institutional Diabetes Endocrinology Research Center (DERC) grant DK32520, a Cancer Center Core grant CA34196, the Beta Cell Biology Consortium, and the Juvenile Diabetes Foundation, International. Human Genome Sciences supplied human recombinant BLyS for some experiments. The contents, study design and interpretation of the data in this publication are solely the responsibility of the authors and do not represent the views of the funding agencies.
###end p 163

